IC50 was 34.19 M, 61.53 M in the senescent fibroblasts from keloid and normal skin, and 93.77 M, 104.6 M in non-senescent control fibroblasts from keloid and normal skin, respectively
Yes, if you are currently receiving treatment from another provider, you may be able to transition your care and continue at a similar or clinically appropriate dose
Immune-mediated skin disorders: Some patients with conditions like psoriasis or hidradenitis suppurativa have reported flares or changes after starting GLP-1RA medications
Regular health checkups, laboratory tests, and professional guidance related to the treatment for high vitamin B12 are key to maintaining a healthy balance and ensuring the early detection of any hidden conditions
If its determined you are a strong candidate for GLP-1 medication, our clinician will work with you to determine if Semaglutide or Tirzepatide works best, and establish a baseline dosage plan